Skip to main content

Advertisement

Table 7 Summary of the sensitivity analysis

From: The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Parameter Hydrocele average estimate Lymphedema average estimate Sources
Disease Progression & Incidence Rates
 Percentage of clinical patients who experience ADL episodes per year 70 % (45–90 %) 95 % (90–95 %) [8, 1017]
 Frequency of ADL episodes for clinical patients (in absence of MDA) 2 (0–7) per year 4 (0–7) per year [8, 1017]
 Average duration of an ADL episode 4 (1–9) days 4 (1–9) days [8, 1017]
 Disability weight for symptomatic LF infection 0.11 (0.073–0.157) 0.11 (0.073–0.157) [40]
 Mean age of the benefit cohorts (years) Cohort 1: 20 (30) Cohort 1: 20 (30)  
Cohort 2: 20 (30) Cohort 2: 20 (30)
Cohort 3: 30 (40) Cohort 3: 30 (40)
Patient Medical Expenses and Treatment Seeking Behavior
 Percentage of patients with ADL seeking treatment per episode 55 % (55–70 %) 55 % (55–70 %) [8, 11, 14, 44, 46]
India 70 % (70–98 %) (India 75 % (75–98 %))
 Percentage of chronic disease patients seeking treatment 20 % (20–50 %) 30 % (30–55 %) [9, 44, 45]
India: 50 % (41–80 %) India 55 % (48–100 %)
 Average patient medical expenses per ADL episode +−20 % of baseline value +−20 % of baseline value [8, 11, 4448]
 Average patient medical expenses for chronic disease per year +−20 % of baseline value +−20 % of baseline value [8, 11, 4448]
Lost Productivity & Wages
 Work days per year 300 (261–365) days 300 (261–365) days  
 Percentage of work hours lost per day during an ADL episode 75 % (50–93 %) 75 % (50–93 %) [12, 14, 16, 87]
 Percentage of work hours lost due to chronic disease 15 % (9–24 %) 19 % (11–31 %) [12, 43, 45, 46]
Discounting
 Discount rate 3 % (0–6 %) 3 % (0–6 %) [59]
Impact of Treatment
 The reduction in transmission experienced by the treated population Year 1: 50 % (35 %) Year 1: 50 % (35 %) [18]
Year 2: 75 % (53 %) Year 2: 75 % (53 %)
Year 3: 88 % (62 %) Year 3: 88 % (62 %)
Year 4: 94 % (66 %) Year 4: 94 % (66 %)
Year 5 95 % (67 %) Year 5 95 % (67 %)
 Reduction in the frequency of ADL episodes by MDA 50 % (15–88 %) 50 % (15–88 %) [33, 36, 37].
 Percentage of chronic disease alleviated by MDA 10 % (0–90 %) 15 % (0–69 %) [20, 3035]
  1. Based on [4], though updated where appropriate. ADL acute adenolymphangitis, MDA mass drug administration